Allen Institute for Artificial Intelligence
supp.ai logo
supp.ai

Discover Supplement-Drug Interactions

Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: a year ago

Possible Interaction: Quinidine and Bufuralol

supplement:

Quinidine

Research Papers that Mention the Interaction

A known inhibitor of CYP2D6, quinidine , effectively inhibited the BF 1"-hydroxylation activities in liver microsomal fractions prepared from KYU- and KAU-marmosets.
Biochemical pharmacology  •  2004  |  View Paper
In inhibition studies, quinidine , a known CYP2D6 inhibitor, markedly inhibited BF 1′′-hydroxylation in the fractions of human liver microsomes that showed the CYP2D6-type selectivity.
Journal of Pharmacology and Experimental Therapeutics  •  2002  |  View Paper
Quinidine inhibited bufuralol 1'-hydroxylation in liver microsomes, particularly at low substrate concentrations, in individuals with CYP2D6*1/*1, and 1/1*2, but not those with CYP2D6*4/*4 and very slightly in individuals with CYP2D6*10B/*10B.
Pharmacogenetics  •  2001  |  View Paper
The 1'-hydroxylation of bufuralol , form selective for CYP2D6, was competitively inhibited by olanzapine (Ki = 89 microM), clozapine (Ki = 19 microM), and quinidine (Ki = 0.03 microM).
British journal of clinical pharmacology  •  1996  |  View Paper
Quinidine and anti-rat P450 2D1 antibody almost completely inhibited bufuralol 1'-hydroxylation in human sample HL-18 at a substrate concentration of 0.4 mM, whereas these effects were not so drastic when liver microsomes from human sample HL-67 were used.
Molecular pharmacology  •  1994  |  View Paper
Inhibition of bufuralol 1'-hydroxylation by quinidine was biphasic in EM microsomes, providing further support for the involvement of at least two cytochrome P-450 isozymes.
Biochemical pharmacology  •  1987  |  View Paper
Quinidine was a potent inhibitor of the 4-hydroxylation of debrisoquine and the 1'-hydroxylation of bufuralol , with IC50 values of 0.7 and 0.2 microM, being around 100 times more potent in this respect than quinine.
British journal of clinical pharmacology  •  1986  |  View Paper
Quinidine , a selective CYP2D inhibitor, decreased the production of both BUF metabolites equally in liver and adrenal microsomes.
Pharmacology  •  2001  |  View Paper